Skip to main content
SleepCited

Chronic idiopathic axonal polyneuropathy and vitamin B6: a controlled population-based study.

Nora A Visser, Nicolette C Notermans, Lieveke A R Degen, Jelle R de Kruijk, Leonard H van den Berg et al.
Other Journal of the peripheral nervous system : JPNS 2014 15 atıf
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D24813907'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Çalışma Türü
Case-Control
Örneklem Büyüklüğü
521
Popülasyon
Patients with chronic idiopathic axonal polyneuropathy
Müdahale
Chronic idiopathic axonal polyneuropathy and vitamin B6: a controlled population-based study. None
Karşılaştırıcı
Healthy controls (n=140)
Birincil Sonuç
Association of vitamin B6 with chronic idiopathic polyneuropathy
Etki Yönü
Negative
Yanlılık Riski
Moderate

Abstract

Vitamin B6 intoxication can result in a sensory ataxic neuropathy, but the association with a milder predominantly sensory or sensorimotor phenotype in chronic idiopathic axonal polyneuropathy (CIAP) remains unclear. A total of 381 patients with CIAP and 140 healthy controls were prospectively included. In a standardized fashion the use of vitamin B6 containing supplements and vitamin B6 levels were compared between patients and controls. On follow-up, patients were questioned about cessation of supplement use and the impact on the symptoms of polyneuropathy. Vitamin B6 levels in patients (median: 99 nmol/l, range: 38-2,967 nmol) were not significantly higher than in controls (median: 109 nmol/l, range: 41-2,373 nmol/l, p = 0.58), nor were daily dose, cumulative dose or duration of supplement use. However, more patients (31%) than controls (22%) used vitamin B6 containing supplements (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.0-2.7, p = 0.032). Follow-up of patients confirming the cessation of supplements showed slow progression of symptoms in 64%, stabilization in 26%, and regression in 10%. On the basis of our prospective case-control study and review of the literature, an association between CIAP and vitamin B6 exposure or elevated vitamin B6 levels appears unlikely.

Kısaca

An association between CIAP and vitamin B 6 exposure or elevated vitamin B6 levels appears unlikely, and follow‐up of patients confirming the cessation of supplements showed slow progression of symptoms, stabilization, and regression.

Used In Evidence Reviews

Similar Papers